G1 Therapeutics Acquisition Finalized in Landmark $405M Deal
Veröffentlicht: 04.09.2025 um 10:27 Uhr, Redaktion boerse-global.deThe biotechnology firm G1 Therapeutics has ceased to be a publicly traded entity following its successful acquisition by the Danish pharmaceutical company Pharmacosmos. Trading of G1 Therapeutics shares was officially halted on all exchanges as the deal reached its formal conclusion.
Pharmacosmos secured the acquisition with a compelling cash offer of $7.15 per share. This price represented a significant 68% premium over the stock’s closing value on the day prior to the deal’s announcement. The transaction, which carried an aggregate value of approximately $405 million, received overwhelming support from G1 Therapeutics’ investors, with 75% of shareholders tendering their shares in favor of the agreement. The final acquisition was completed on September 18, 2024, prompting the immediate delisting of the company’s stock from the NASDAQ Read more...
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
